Access Vascular Prepares Catheter Location Technology for FDA Submission
24 July 2024 - 12:06PM
Business Wire
New Technology to Expand Access Vascular’s
Reach Into the $520 million Peripherally Inserted Central
Catheter (PICC) Market
Access Vascular, Inc. (AVI), a medical device company dedicated
to reducing and eliminating common and costly vascular access
complications with its novel MIMIX® catheter material, announced
today that it is preparing to submit its HydroGUIDE™ catheter
placement technology for U.S. Food & Drug Administration (FDA)
clearance.
Nearly two-thirds of the more than 2.7 million PICCs placed each
year are guided by catheter locating technology, allowing the
devices to be placed at the bedside by skilled nursing staff.
Although AVI catheters are compatible with many catheter placement
systems, the addition of AVI’s HydroGUIDE™ technology to the AVI
product lineup reinforces its commitment to advancing vascular
access and paves the way for future portfolio additions.
HydroGUIDE™ will allow nurses to combine the benefits of AVI’s
award-winning MIMIX® catheters with the ability to determine
appropriate catheter placement – without leaving the patient’s
room.
HydroGUIDE is designed to fit seamlessly into existing clinical
workflows with minimal capital expense, while offering the
convenience of a highly mobile solution. Its patient-centric design
prioritizes accuracy and ease of use, enabling real-time
information to guide clinicians in making precise adjustments
during catheter placement.
“Combining the innovative HydroGUIDE™ catheter tip location
technology with AVI’s platform of MIMIX® vascular access devices
creates a value-based solution for PICC line placement that
ultimately may reduce complications and improve patient care,” said
Lee Steere, Manager of IV Therapy Services for Hartford Hospital.
“Access Vascular is positioned to make a significant difference in
outcomes for vascular access patients.”
AVI’s proprietary MIMIX® technology imitates the body’s natural
chemistry to evade the foreign body response and its associated
complications. Data from multiple studies of catheters made using
MIMIX® (the HydroPICC®, HydroPICC® Dual, and HydroMID® devices) has
demonstrated significantly lower rates of complications associated
with vascular access devices – with the potential for significant
hospital savings and an improved patient experience.
AVI's FDA-cleared devices have been shown to lower complication
rates by a factor of six, compared with standard catheters, and an
in vitro study demonstrated a 99.99% reduction in bacterial
adhesion.1,2 For patients, this could mean fewer infections, less
time in the hospital, and reduced risk of long-term health
issues.
About Access Vascular
Access Vascular was founded to address the most common and
costly complications of intravenous therapy: infection, thrombosis,
and phlebitis. Taking a foundationally different approach to
thrombus reduction, the company manufactures intravenous catheters
from a hydrophilic material. Engineered to mimic the body’s natural
chemistry, Access Vascular’s MIMIX®-based catheters are designed to
evade the foreign body response and complications that come with
it. Our award-winning, FDA-cleared products are HydroPICC® and
HydroMID®. For more information, please visit our website, and
follow us on LinkedIn.
1 Bunch J. A retrospective assessment of peripheral midline
failures focusing on catheter composition. J InfusNurs. Sept/Oct
2022; 45(5):270-27. doi: 10.1097/NAN.0000000000000484 2 LeRoy, K.
J. 2023 Association for Vascular Access Scientific Meeting: Poster
Abstracts. Journal of the Association for Vascular Access 1 May
2024; 29 (2): 51–66. doi:
https://doi.org/10.2309/1557-1289-29.2.51
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240724105938/en/
Brad Perriello Circle Hill Communications
brad@circlehillcommunications.com 617.817.1385